ENGINEERED INFLUENZA VIRUSES EXPRESSING SARS-COV-2 ANTIGENS, VACCINES AND METHODS OF MAKING AND USING THE SAME

The present invention provides engineered polynucleotides encoding both the receptor binding domain (RBD) of a SARS-CoV-2 spike protein and an influenza hemagglutinin (HA) protein. Also provided are influenza viruses that comprise the engineered polynucleotides and express both the RBD and HA protei...

Full description

Saved in:
Bibliographic Details
Main Authors Harding, Alfred, Heaton, Nicholas, Heaton, Brook, Chaparian, Ryan
Format Patent
LanguageEnglish
Published 27.06.2024
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The present invention provides engineered polynucleotides encoding both the receptor binding domain (RBD) of a SARS-CoV-2 spike protein and an influenza hemagglutinin (HA) protein. Also provided are influenza viruses that comprise the engineered polynucleotides and express both the RBD and HA protein on their surface and methods for using these influenza viruses to generate an immune response to both influenza and SARS-CoV-2 in a subject.
Bibliography:Application Number: US202218557787